Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 7/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.51 |
| ▸ | PDE4A | P27815 | 2/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7134735 | 0.92 | PDK2 (0.71) | IDO1PDK2PDK4PGRLMNA | |
| SCHEMBL1223198 | 0.85 | PDK2 (0.55) | IDO1PDK2PDK4PGRLMNA | |
| SCHEMBL29519108 | 0.85 | PDK2 (0.55) | IDO1PDK2PDK4PGRLMNA | |
| SCHEMBL2452451 | 0.84 | LMNA (0.42) | IDO1PGRLMNAALDH1A1MEN1 | |
| SCHEMBL29399343 | 0.84 | LMNA (0.42) | IDO1PGRLMNAALDH1A1MEN1 | |
| SCHEMBL3524533 | 0.81 | LMNA (0.57) | IDO1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL3524585 | 0.80 | PGR (0.85) | PGRLMNAPDE3BPDE3APDE4A | |
| SCHEMBL22632577 | 0.79 | MEN1 (0.51) | IDO1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL3525683 | 0.79 | LMNA (0.55) | IDO1PGRLMNAALDH1A1MEN1 | |
| SCHEMBL5499896 | 0.79 | LMNA (0.48) | LMNAALDH1A1MEN1KMT2AAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | claimed |
| JP-2003508387-A | — | — | 2003-03-04 | — | — | JP | claimed |
| CN-1382124-A | Bicyclic androgen and progesterone receptor modulating compounds and methods | LIGAND PHARM INC (US) | 2002-11-27 | — | — | CN | claimed |
| EP-1212303-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2001016108-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | claimed |
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2026-05-28 | — | — | US | disclosed |
| CN-122036699-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-4720037-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4676590-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | Zoetis Services LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250376463-A1 | PROTEIN DEGRADATION AGENT COMPOUND PREPARATION METHOD AND APPLICATION | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2025-12-11 | — | — | US | disclosed |
| WO-2000031074-A2 | INDOLE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR LIGANDS | ELI LILLY AND COMPANY LIMITED (GB) | 2000-06-02 | — | — | WO | disclosed |
| EP-0963983-A1 | Indol-2-ones as serotonin modulators | ELI LILLY AND COMPANY LIMITED (GB) | 1999-12-15 | — | — | EP | disclosed |
| WO-1999058525-A1 | INDOLE DERIVATIVES AS 5-HT2A LIGANDS AND AS SEROTONINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY LIMITED (GB) | 1999-11-18 | — | — | WO | disclosed |
| US-5773448-A | NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY LIMITED (GB) | 1998-06-30 | — | — | US | disclosed |
| CN-1157822-A | Pharmaceutical compounds | LILLY INDUSTRIES LTD (GB) | 1997-08-27 | — | — | CN | disclosed |
| EP-0780388-A1 | 5HT1Dalpha and 5HT2A ligands | LILLY INDUSTRIES LIMITED (GB) | 1997-06-25 | — | — | EP | disclosed |
| US-4898872-A | Imidazo[4,5-b]pyridyl quinolone cardiac stimulants | PFIZER INC. (US) | 1990-02-06 | — | — | US | disclosed |
| EP-0290153-A1 | Heterobicyclic quinolone derivatives | Pfizer Limited (GB) | 1988-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376463-A1 | PROTEIN DEGRADATION AGENT COMPOUND PREPARATION METHOD AND APPLICATION | AR, PSMA8, PSMA6 | IDO1 3513/4885PDK2 1935/4885PDK4 1953/4885 |
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | AXL, ERBB2, ERBB3 | IDO1 37/4885PDK2 2782/4885PDK4 2199/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | IDO1 348/4885PDK2 2142/4885PDK4 1772/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | IDO1 2570/4885PDK2 520/4885PDK4 469/4885 |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | IDO1 1719/4885PDK2 1528/4885PDK4 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.